---
schema_version: "secwatch.filing_event.v1"
accession: "0001641172-25-010873"
form_type: "8-K"
ticker: "BGMS"
cik: "0001130166"
company_name: "Bio Green Med Solution, Inc."
filed_at: "2025-05-15T23:59:59+00:00"
generated_at: "2026-05-21T04:32:22.143830+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Cyclacel Pharmaceuticals Q1 2025: Deconsolidation Gain, FITTERS Exchange, Focus on Plogosertib

## Summary
- Cyclacel reported Q1 2025 net loss of $0.1 million, compared to $2.9 million in Q1 2024.
- Deconsolidation of UK subsidiary Cyclacel Limited resulted in a $5.0 million gain on deconsolidation.
- Company repurchased plogosertib assets from Cyclacel Limited for approximately $0.3 million.
- Entered into an Exchange Agreement with FITTERS Diversified Berhad to acquire Fitters Sdn. Bhd. for 19.99% of common stock.
- Cash and cash equivalents totaled $3.5 million as of March 31, 2025, expected to fund into Q2 2025.

## SEC filing metadata
- accession: 0001641172-25-010873
- form_type: 8-K
- ticker: BGMS
- cik: 0001130166
- company_name: Bio Green Med Solution, Inc.
- filed_at: 2025-05-15T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1130166/000164117225010873/0001641172-25-010873-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1130166/000164117225010873/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641172-25-010873
- JSON: https://secwatch.observer/filing/0001641172-25-010873.json
- Plain text: https://secwatch.observer/filing/0001641172-25-010873.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.